Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

12:18
06/23/18
06/23
12:18
06/23/18
12:18

Eli Lilly's Trulicity shows promise in delivering efficacy in type 2 diabetes

Two investigational doses of Lilly's dulaglutide - 4.5 mg and 3.0 mg -, as well as Trulicity 1.5 mg, provided significantly better blood sugar control with weight benefits compared to placebo in adults with type 2 diabetes. Trulicity is Eli Lilly's once-weekly, injectable glucagon-like peptide-1 receptor agonist approved to improve blood sugar in adults with type 2 diabetes. At the study's primary endpoint of 18 weeks, the investigational dulaglutide 4.5 mg and 3.0 mg doses, as well as the currently approved Trulicity 1.5 mg dose, led to superior A1C reductions from baseline in people with type 2 diabetes who remained on treatment throughout the study compared to placebo. The investigational dulaglutide doses also led to significant weight loss compared to placebo, as did Trulicity 1.5 mg. The most commonly reported side effects were gastrointestinal-related and consistent with the GLP-1 RA class. These events included nausea. Trulicity 1.5 mg had a similar side effect profile to previous studies. No participants in any of the treatment groups experienced severe hypoglycemia. The safety and efficacy of the dulaglutide investigational doses are being studied further in a large, Phase 3 clinical trial, AWARD-11. The study is expected to complete in 2019.

  • 10

    Sep

LLY Eli Lilly
$85.90

-0.17 (-0.20%)

06/11/18
WELS
06/11/18
NO CHANGE
Target $240
WELS
Outperform
Allergan migraine data on lower end of relative efficiency, says Wells Fargo
Wells Fargo analyst David Maris says his initial review suggests Allergan's (AGN) atogepant's Phase IIb data are "relatively in-line but on the lower end of the efficacy" demonstrated by the calcitonin gene-related peptide migraine treatments in Phase III trials. Atogepant is expected to face competition from Amgen (AMGN)/Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), which are all developing injectable anti-CGRP treatments, as well as Alder Biopharmaceuticals (ALDR), which has an infusion-administered anti-CGRP in development, Maris tells investors in a research note. He notes that while Allergan will be following these competitors to the market, atogepant will be differentiated in that it is the only oral prophylactic anti-CGRP therapy. The analyst forecasts $75M in sales for atogepant in 2022. He does not believe many investors are giving Allergan credit for atogepant, meaning the "risk to the downside looks limited." Maris keeps an Outperform rating on Allergan shares.
06/13/18
JEFF
06/13/18
DOWNGRADE
Target $50
JEFF
Hold
Armo BioSciences downgraded to Hold from Buy at Jefferies
Jefferies analyst Biren Amin downgraded Armo BioSciences (ARMO) to Hold and lowered his price target for the shares to $50 from $61. The analyst expects the takeover by Eli Lilly (LLY) to close in a few weeks and does not expect a competing bid to emerge.
06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/15/18
PIPR
06/15/18
NO CHANGE
Target $85
PIPR
Overweight
Piper Jaffray sees better than expected U.S. launch for Olumiant
Piper Jaffray analyst Tyler Van Buren says he left a meeting with CEO of Eli Lilly (LLY) David Ricks with increased conviction in the U.S. launch of Olumiant. The analyst believes the launch will be better than investors currently anticipate and reiterates an Overweight rating on shares of Incyte (INCY) with an $85 price target. Van Buren expect payors to be "very receptive" to Olumiant pricing.

TODAY'S FREE FLY STORIES

CREE

Cree

$46.92

0.58 (1.25%)

16:16
07/18/18
07/18
16:16
07/18/18
16:16
Initiation
Cree initiated  »

Cree initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

EBAY

eBay

$37.95

0.13 (0.34%)

16:16
07/18/18
07/18
16:16
07/18/18
16:16
Earnings
eBay reports Q2 EPS 53c, consensus 51c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/18/18
07/18
16:16
07/18/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMI

Badger Meter

$46.95

1.2 (2.62%)

16:16
07/18/18
07/18
16:16
07/18/18
16:16
Earnings
Badger Meter reports Q2 adjusted EPS 42c, consensus 39c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

BHLB

Berkshire Hills Bancorp

$40.80

0.15 (0.37%)

16:15
07/18/18
07/18
16:15
07/18/18
16:15
Earnings
Berkshire Hills Bancorp reports Q2 EPS 74c, consensus 70c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

LONE

Lonestar Resources

$10.37

0.42 (4.22%)

16:15
07/18/18
07/18
16:15
07/18/18
16:15
Initiation
Lonestar Resources initiated  »

Lonestar Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

LGF.A

Lionsgate

$23.88

-0.595 (-2.43%)

, LGF.B

Lionsgate

$22.65

-0.3 (-1.31%)

16:14
07/18/18
07/18
16:14
07/18/18
16:14
Upgrade
Lionsgate, Lionsgate rating change  »

Lionsgate upgraded to Buy…

LGF.A

Lionsgate

$23.88

-0.595 (-2.43%)

LGF.B

Lionsgate

$22.65

-0.3 (-1.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

EGAN

eGain

$13.18

-0.725 (-5.22%)

16:13
07/18/18
07/18
16:13
07/18/18
16:13
Initiation
eGain initiated  »

eGain initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLX

Clorox

$129.46

-5.54 (-4.10%)

16:12
07/18/18
07/18
16:12
07/18/18
16:12
Initiation
Clorox initiated  »

Clorox initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

AA

Alcoa

$47.85

-0.155 (-0.32%)

16:12
07/18/18
07/18
16:12
07/18/18
16:12
Hot Stocks
Alcoa cuts FY18 adjusted EBITDA view to $3B-$3.2B from $3.5B-$3.7B »

The new full-year…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

TBK

Triumph Bancorp

$41.15

0.45 (1.11%)

16:12
07/18/18
07/18
16:12
07/18/18
16:12
Earnings
Triumph Bancorp reports Q2 adj. EPS 50c, consensus 50c »

Adjusted diluted earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 31

    Jul

  • 24

    Sep

AXP

American Express

$102.98

1.84 (1.82%)

16:12
07/18/18
07/18
16:12
07/18/18
16:12
Hot Stocks
American Express says resuming buybacks this quarter »

Q2 consolidated total…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 08

    Aug

ON

ON Semiconductor

$24.24

0.34 (1.42%)

16:12
07/18/18
07/18
16:12
07/18/18
16:12
Initiation
ON Semiconductor initiated  »

ON Semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 07

    Aug

  • 08

    May

BMCH

BMC Stock Holdings

$21.70

0.1 (0.46%)

16:11
07/18/18
07/18
16:11
07/18/18
16:11
Initiation
BMC Stock Holdings initiated  »

BMC Stock Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

AA

Alcoa

$47.94

-0.065 (-0.14%)

16:10
07/18/18
07/18
16:10
07/18/18
16:10
Earnings
Alcoa reports Q2 EPS ex-items $1.52, consensus $1.34 »

Reports Q2 revenue $3.6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

AXP

American Express

$102.96

1.82 (1.80%)

16:10
07/18/18
07/18
16:10
07/18/18
16:10
Hot Stocks
American Express reaffirms FY18 EPS view at high-end of $6.90-$7.30 view »

FY18 EPS consensus $7.24.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 08

    Aug

KMI

Kinder Morgan

$17.77

0.075 (0.42%)

16:09
07/18/18
07/18
16:09
07/18/18
16:09
Earnings
Kinder Morgan backs FY18 adjusted EBITDA view of roughly $7.5B »

For 2018, KMI's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

FBNK

First Connecticut

$30.95

(0.00%)

16:09
07/18/18
07/18
16:09
07/18/18
16:09
Earnings
First Connecticut reports Q2 EPS 42c, consensus 40c »

Net interest income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXP

American Express

$102.93

1.79 (1.77%)

16:08
07/18/18
07/18
16:08
07/18/18
16:08
Earnings
American Express reports Q2 EPS $1.84, consensus $1.82 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 08

    Aug

KMI

Kinder Morgan

$17.80

0.11 (0.62%)

16:08
07/18/18
07/18
16:08
07/18/18
16:08
Earnings
Kinder Morgan reports Q2 adjusted EPS 21c, consensus 19c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

GBNK

Guaranty Bancorp

$30.70

0.25 (0.82%)

16:08
07/18/18
07/18
16:08
07/18/18
16:08
Earnings
Breaking Earnings news story on Guaranty Bancorp »

Guaranty Bancorp reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTC

PTC

$98.27

-0.64 (-0.65%)

16:08
07/18/18
07/18
16:08
07/18/18
16:08
Hot Stocks
PTC advances transition to subscription business model »

PTC announced a milestone…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

GBX

Greenbrier

$55.10

0.25 (0.46%)

16:08
07/18/18
07/18
16:08
07/18/18
16:08
Initiation
Greenbrier initiated  »

Greenbrier initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UFPI

Universal Forest

$38.35

-0.205 (-0.53%)

16:07
07/18/18
07/18
16:07
07/18/18
16:07
Earnings
Universal Forest reports Q2 EPS 71c, consensus 73c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLG

SL Green Realty

$100.51

0.29 (0.29%)

16:07
07/18/18
07/18
16:07
07/18/18
16:07
Earnings
SL Green Realty reports Q2 FFO $1.69, consensus $1.68 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.